Introduction
tetanus
CURBING, VIRUS, TETANUS
Vaccines have been considered one of the most important interventions for curbing the COVID-19 pandemic. COVID-19 vaccine studies have been conducted based on different approaches including the first-generation platforms (eg, attenuated and inactivated virus vaccines), the second-generation vaccines, such as replicating vector vaccines and protein-based vaccines (eg, subunit and viral vectors), and the third-generation vaccines, such as nanoparticle and genetic vaccines (eg, DNA/RNA vaccines).FINLAY-FR-2 (Soberana 02) is a protein subunit vaccine conjugated to the tetanus toxoid carrier protein and has shown potential in preclinical studiesOn approval of the first sets of COVID-19 vaccines, governments all over the world rushed to place orders for supplies, based on the assumed effectiveness and relevance of the vaccine for their populations. While the recent launch of several safe and efficient COVID-19 vaccines has offered hope to tens of millions of people, vaccine supply is limited in low-income countries where the governments face supply challenges posed by vaccine cost as well as storage and transportation conditions.We report a double-blind, randomized, placebo-controlled phase 3 vaccine trial to assess the efficacy, safety, and immunogenicity of FINLAY-FR-2 with the third dose of FINLAY-FR-1A, 50 μg, in Iran, as a country that has not reported on many trials.